Annette Bianchi
Managing Director @ VantagePoint Capital Partners
San Bruno, United States
Annette Bianchi is a Series B investor at VantagePoint Capital Partners in San Bruno focused on Health Care and Biotechnology. Annette joined VantagePoint in 2004 and leads the Healthcare Practice Group. She has 24 years of venture capital experience, with significant expertise in all areas of healthcare investing, including medical devices, biotechnology, and healthcare information technology and services. She began her career in venture capital in 1985 at Burr, Egan,Deleage & Company, later joining Weiss, Peck & Greer Venture Partners as a General Partner. In 1999, she became a Managing Director at Pacific Venture Group. Annette is a graduate of University of Pennsylvania (BSE and MSE in Biomedical Engineering) and The Wharton School (MBA).
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Annette Bianchi invests in
Stages Annette Bianchi invests in
Countries Annette Bianchi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (38%)
- Biotechnology 2 (25%)
- Pharmaceutical 2 (25%)
- Medical 1 (13%)
- Medical Device 1 (13%)
Stage
- Series B 2 (25%)
- Funding Round 2 (25%)
- Series A 1 (13%)
- Series C 1 (13%)
- Venture - Series Unknown 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments forAmyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners | $14.9M / Venture - Series Unknown / May 24, 2016 | ||
| Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $284K / Apr 01, 2012 | ||
| Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments forAmyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners | $9.6M / Series B / Jan 31, 2012 | ||
| Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $40M / Series C / Oct 05, 2009 | ||
| Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments forAmyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners | $17M / Series A / Mar 26, 2009 | ||
| Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies forthe treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California. | $19M / Aug 14, 2008 | ||
| Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgicallytreated each year. | $27M / Series B / Oct 19, 2007 | ||
| Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies forthe treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California. |
Co-Investors
VantagePoint Capital Partners (formerly VantagePoint Venture Partners, until 2011) has more than $4.5 billion in capital under management and invests in the cleantech, healthcare, and IT sectors.
VantagePoint Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan Salzman
Co-Founder and Managing Partner
|
|||
|
Annette Bianchi
Managing Director
|
|||
Bill Green
Managing Director
|
|||
Bill Harding
Managing Director
|
|||
David Vieau
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Annette Bianchi invest in?
Annette Bianchi invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Annette Bianchi?
Public channels for Annette Bianchi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Annette Bianchi last invest?
The most recent investment recorded for Annette Bianchi closed in May 2016. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
